• Pieris receives funding to develop drug for long COVID treatment pharmaceutical-technology
    June 28, 2021
    US-based Pieris Pharmaceuticals has received a funding grant to develop PRS-220 to treat post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF), also called post-COVID-19 syndrome pulmonary fibrosis or long COVID.
PharmaSources Customer Service